Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer [0.03%]
表皮生长因子受体阳性非小细胞肺癌一线治疗选择指南
Giulia La Cava,Alessio Cortellini,Julia K Rotow et al.
Giulia La Cava et al.
The discovery of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) and the subsequent development of targeted therapeutics represents a groundbreaking advancement in care, shifting the treatment paradig...
Implementing Evidence-Based Strategies to Improve Pediatric Oncology Infection Management [0.03%]
基于证据的策略在改善儿科肿瘤感染管理中的实施
L Lee Dupuis,Venkatraman Radhakrishnan,Sara E Manning et al.
L Lee Dupuis et al.
Every year, many children around the world are diagnosed with cancer. While the overall survival of pediatric patients with cancer is high and constantly improving with clinical trials and adjustments to existing treatment protocols, many o...
Taking a Bite Out of Small Cell Lung Cancer By Leveraging Precision-Directed Delta-Like Ligand-3 Therapies [0.03%]
利用精确导向的Delta样配体-3疗法对抗小细胞肺癌
Ayesha Aijaz,Sagal Pannu,Hassan Abushukair et al.
Ayesha Aijaz et al.
The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)-directed therapies, particularly tarlatamab, a first-in-class bispecific T-cell engager designed to b...
Autologous T-Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities [0.03%]
自体T细胞治疗在实体瘤中的现状与未来机遇
Daniel Reinhorn,Willemijn S Tak,John B A G Haanen et al.
Daniel Reinhorn et al.
Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma, leukemia, and multiple myeloma. Treatm...
Leveling Up: Harnessing Cutting-Edge Technology to Enhance Oncology Education and Learning [0.03%]
更上一层楼：利用尖端技术增强肿瘤学教育和学习
Eleonora Teplinsky,Tae Hoon Kim,Stephanie Haddad et al.
Eleonora Teplinsky et al.
The integration and utilization of digital media, gamified learning strategies, and artificial intelligence (AI) are fundamentally transforming the landscape of oncology education and learning. These technologies collectively enhance knowle...
Maria Daca-Álvarez,Angelo Brunori,Alessio Carbone et al.
Maria Daca-Álvarez et al.
Chemoprevention has emerged as a promising strategy to reduce cancer incidence by using pharmacologic agents that interrupt the carcinogenesis process. This review discusses emerging insights and recent advancements in chemoprevention, emph...
Sue Zupanec,Melissa Beauchemin,Rachel E Rau
Sue Zupanec
Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)-positive adult B-ALL in 2018, its indications have since expanded aft...
Is Less More? Maximizing Outcomes by Tailoring Treatments to Patients: Oncofertility and Oncomenopause [0.03%]
更少即是更多吗？通过治疗手段的个体化选择来实现最优预后——论肿瘤与生育及绝经期管理的关系
Janice S Kwon,Marie Plante,Martha Hickey et al.
Janice S Kwon et al.
Notable advances have been made in improving survival outcomes in various cancers, but some have incurred undesirable costs and effects to patients with respect to fertility and menopause. Patients are living longer with cancer, and patient...
Capturing Unicorns: Targeting Cancers With TP53 Mutations, RAS Alterations Beyond G12C, and MTAP Loss-No Target Is Out of the Realm of Possibility [0.03%]
捕获“独角兽”：靶向TP53突变、G12C以外的RAS改变和MTAP丢失肿瘤-没有“不可能”的靶点
Pooja A Shah,Klas G Wiman,Karen Cichowski et al.
Pooja A Shah et al.
In cancer genomics, there is the realization that some very frequently mutated genes like TP53 or KRAS are extremely hard to approach from a therapeutic perspective. In the realm of cancer treatment, the development of agents capable of tra...
Bin Lian,Jun Guo
Bin Lian
Mucosal melanoma (MM) is a rare and aggressive subtype of melanoma arising from mucosal tissues, with distinct genomic and clinical characteristics compared with cutaneous melanoma (CM). Despite therapeutic advancements, MM remains challeng...